All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2017-05-05.
From the record
Agios Pharmaceuticals, Inc.'s filings since 2017 show 1 warning event: an auditor change (8-K item 4.01, the latest 2017-05-05) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-2.8% a year over 10 filed years; profitable in 2 of 10.
From the record
Agios Pharmaceuticals, Inc.'s 10 filed years say what it did: revenue went from $70 million in fiscal 2016 to $54 million in fiscal 2025, down 2.8% a year; it rose in 5 of 7 years; the deepest fall was 100% from fiscal 2019 to fiscal 2020; net income was positive in 2 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 8.0/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Agios Pharmaceuticals, Inc.'s shareholder treatment is put at 8.0 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 20% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -35%: lost 35¢ per shareholder dollar. Leverage 8%: owes 8¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Agios Pharmaceuticals, Inc. lost about 35 cents for every dollar of shareholders' money, and gross profitability: its products earned about 4 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 8 cents per dollar of assets, and net share issuance: its share count grew 0.1% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 44% of 315 in its family; net margin -764%.
From the record
Agios Pharmaceuticals, Inc.'s standing among 315 graded names in its industry family: revenue of $54 million in fiscal 2025 ranks in the top 43% by size; a net margin of -764% ranks in the bottom 33%; revenue growth of 56% a year over the last 3 filed years ranks in the top 22% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 49% of 315 in its family for leadership; chief executive since 2022.
From the record
Agios Pharmaceuticals, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Goff, Brian (Chief Executive Officer, as filed), filing under that title since 2022-08-09, 4.3 years (bottom 42% of its family); the 16 officers and directors filing in the last fifteen months have been on the record a median of 4.3 years (bottom 26%); 4 officer or director changes were reported on Form 8-K since 2023-11-13, against the 16 people in charge now (top 23%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 49% of 273 in its family for room to expand.
From the record
Agios Pharmaceuticals, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $89 million against no long-term debt tagged leaves 6.9% of its assets as net cash, bottom 21% of its family; cash from operations less capital spending is -698.3% of revenue (bottom 29%); a gross margin of 88.3% (top 20%); research spending of 628.4% of revenue (top 26%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 30% of 306 in its family for growth drivers.
From the record
Agios Pharmaceuticals, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 56% a year over the last three filed years against -2.8% over all 10, speeding up (top 8% of its family); the newest year grew 48.1% (top 27%); research spending grew 6.6% a year (top 44%); capital spending grew -4% a year (top 42%) (its annual reports). Agios Pharmaceuticals, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 20% of 233 in its family for expectations against reality.
From the record
Agios Pharmaceuticals, Inc.'s newest year against its own record: revenue of $54 million in fiscal 2025 came in 7.5% below the $58 million its prior three years' pace pointed to (bottom 42% of its family); net income of $413 million against a prior three-year average of $30 million (bottom 3%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 15%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made